{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-025304","form_type":"8-K","ticker":"TGTX","cik":"0001001316","company_name":"TG THERAPEUTICS, INC.","filed_at":"2026-08-03T11:05:58+00:00","discovered_at":"2026-08-03T11:10:00.393513+00:00","generated_at":"2026-08-03T11:10:12.966969+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"TG Therapeutics Q2 2026 revenue $240M, raises FY2026 BRIUMVI guidance to ~$890-905M","bullets":["Q2 2026 total global revenue ~$240M; BRIUMVI U.S. net product revenue $227.7M, up 64% YoY.","Raises FY2026 BRIUMVI U.S. net product revenue target to ~$890-905M; total global revenue target ~$950M.","Net income $7.8M in Q2 2026 vs $28.2M in Q2 2025; R&D expense increased to $95.3M due to subcutaneous manufacturing.","Positive Phase 3 ENHANCE trial met primary endpoint; single 600mg infusion regimen eliminates Day 15 infusion.","Cash position $612.3M as of June 30, 2026; operating expense target $350-400M (excl. non-cash comp) plus ~$100M for subcutaneous mfg."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-025304","json":"https://secwatch.observer/filing/0001437749-26-025304.json","markdown":"https://secwatch.observer/filing/0001437749-26-025304.md","text":"https://secwatch.observer/filing/0001437749-26-025304.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001316/000143774926025304/0001437749-26-025304-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001316/000143774926025304/tgtx20260730_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-03T11:10:12.966969+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}